NCT00973882View on ClinicalTrials.gov

Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

January 31, 2010

Conditions
Prostate Cancer
Interventions
DRUG

Carboplatin

Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles

DRUG

Etoposide

Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles

Trial Locations (11)

13273

Institut Paoli Calmette, Marseille

14021

Centre François Baclesse, Caen

21000

Centre Georges François Leclerc, Dijon

34298

Centre Val d'Aurelle, Montpellier

69008

Centre Leon Berard, Lyon

75005

Institut Curie, Paris

75674

Fondation Hôpital Saint-Joseph, Paris

75908

Hopital Européen Georges Pompidou, Paris

85925

Centre Hospitalier Départemental Les Oudairies, La Roche-sur-Yon

92151

Hopital Foch, Suresnes

94000

Hôpital Henri Mondor, Créteil

All Listed Sponsors
lead

Centre Leon Berard

OTHER

NCT00973882 - Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers | Biotech Hunter | Biotech Hunter